InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: Waitforit53 post# 37989

Thursday, 01/12/2017 7:39:37 PM

Thursday, January 12, 2017 7:39:37 PM

Post# of 48316
Hi Wait, did you notice the second bullet in the bottom section of slide 26 of the Biotech Showcase presentation?
https://staticseekingalpha1.a.ssl.fastly.net/uploads/sa_presentations/300/4300/slides/26.jpg?1484237754

This is the first time they have listed partnership as part of 12 month milestones.
They've mentioned partnerships before but in other contexts, maybe under strategy, but never under 12 month milestones. What's also worthy of noting is partnership(s) for "melanoma and solid tumor indications." If these are going to be with one big pharma (MRK), I believe we can expect a decent deal amount. My bet is on NSCLC.

Given patient enrollment for melanoma registration trial is expected to start in Q2 2017, I expect the long-awaited partnership to be announced this quarter.

As for TRACE, as hschlauch has written about it, and as Punit also said during yesterday's presentation, it seems ready to be used for combinations beyond anti-PD1 agents. Will be exciting to find out who their collaborators are going to be on this one. If I had to guess, KU Leuven and a big pharma will team up on something.

Looking forward to these inflection points this year.